{"id":"dex","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dry mouth"},{"rate":"10-20%","effect":"Hypotension"},{"rate":"5-10%","effect":"Bradycardia"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":{"setId":"015b47e1-4afe-48a3-86ff-06f404d48ad5","title":"NIGHT TIME COLD AND FLU (ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE) LIQUID [THE KROGER CO.]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Dexmedetomidine works by activating alpha-2 adrenergic receptors in the brain, which leads to a decrease in the activity of the sympathetic nervous system. This results in sedation, anxiolysis, and a decrease in blood pressure and heart rate. Additionally, dexmedetomidine has analgesic properties and can reduce the need for opioids in some patients.","oneSentence":"Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that induces sedation and reduces sympathetic nervous system activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:22.730Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Sedation in intensive care unit (ICU) patients"},{"name":"Sedation in procedural sedation"}]},"trialDetails":[{"nctId":"NCT07497009","phase":"NA","title":"Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial.","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-12-23","conditions":"Neurocognitive Function of Elderly Patients Post Operation","enrollment":30},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT03798678","phase":"PHASE1","title":"CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-08","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":36},{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT07463807","phase":"PHASE1, PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":162},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":80},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT04847453","phase":"PHASE1","title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-03","conditions":"Recurrent AL Amyloidosis, Refractory AL Amyloidosis","enrollment":24},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":525},{"nctId":"NCT05519085","phase":"PHASE3","title":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","status":"RECRUITING","sponsor":"Celgene","startDate":"2022-09-20","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":810},{"nctId":"NCT02773030","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":"Multiple Myeloma","enrollment":466},{"nctId":"NCT02491632","phase":"PHASE2, PHASE3","title":"Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-08-13","conditions":"Advanced Malignant Neoplasm, Fatigue, Metastatic Malignant Neoplasm","enrollment":90},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT06918431","phase":"PHASE2","title":"Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-10","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma","enrollment":53},{"nctId":"NCT05552976","phase":"PHASE3","title":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-01-10","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":525},{"nctId":"NCT07475156","phase":"PHASE4","title":"The Effect of Dexmedetomidine Infusion Alone Versus the Combination of Dexmedetomidine and Melatonin on Reduction of Post-operative Delirium (POD) After Open Brain Surgeries","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2025-08-01","conditions":"Post Operative Delerium","enrollment":100},{"nctId":"NCT07023120","phase":"PHASE4","title":"PENG Block Optimization: Volume and Dexamethasone Effects","status":"COMPLETED","sponsor":"Poznan University of Medical Sciences","startDate":"2025-06-25","conditions":"Hip Arthropathy, Hip Osteoarthritis, Hip Arthritis","enrollment":120},{"nctId":"NCT04883242","phase":"PHASE2","title":"Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT07470775","phase":"PHASE4","title":"Early Dexmedetomidine and Sympathetic Regulation in Sepsis","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Academy of Medical Sciences","startDate":"2026-03-01","conditions":"Sepsis, Septic Shock","enrollment":168},{"nctId":"NCT06867289","phase":"NA","title":"Study of the Efficacy of Moderate Sedation With Intra-NAsal Dexmedetomidine Monitored by EEG MOnitoring","status":"RECRUITING","sponsor":"Centre Hospitalier Régional Metz-Thionville","startDate":"2025-04-08","conditions":"Procedural Sedation and Analgesia, Pediatric ALL","enrollment":50},{"nctId":"NCT07465185","phase":"PHASE2","title":"Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery","status":"RECRUITING","sponsor":"Benha University","startDate":"2026-03-15","conditions":"Anesthesia","enrollment":300},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT06203912","phase":"PHASE1","title":"Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elvira Umyarova","startDate":"2024-03-05","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":3},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":"Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":40},{"nctId":"NCT07442890","phase":"NA","title":"A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-04-30","conditions":"Lung Cancer","enrollment":238},{"nctId":"NCT03937635","phase":"PHASE3","title":"Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-09-16","conditions":"Smoldering Plasma Cell Myeloma","enrollment":288},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":"Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma","enrollment":1450},{"nctId":"NCT07443085","phase":"PHASE2","title":"Effect of Dexmedetomidine Dosage on Postoperative Delirium in Geriatric Orthopedic Surgery","status":"RECRUITING","sponsor":"Benha University","startDate":"2026-02-26","conditions":"Delirium - Postoperative","enrollment":75},{"nctId":"NCT07438119","phase":"PHASE4","title":"Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients","status":"NOT_YET_RECRUITING","sponsor":"Kun Liu","startDate":"2026-03-15","conditions":"Diabetic Macular Edema (DME)","enrollment":114},{"nctId":"NCT03283917","phase":"PHASE1","title":"Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-07","conditions":"Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis","enrollment":21},{"nctId":"NCT04764942","phase":"PHASE1, PHASE2","title":"Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2021-05-06","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":39},{"nctId":"NCT07315880","phase":"","title":"Extracellular Fluid Changes During Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Florence Nightingale Hospital, Istanbul","startDate":"2021-01-01","conditions":"Lymphedema Arm","enrollment":111},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT07082270","phase":"PHASE1","title":"Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-01","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":21},{"nctId":"NCT02339740","phase":"PHASE3","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-07-21","conditions":"Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","enrollment":158},{"nctId":"NCT04754945","phase":"PHASE1","title":"Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-04-28","conditions":"AL Amyloidosis","enrollment":11},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":"Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia","enrollment":42},{"nctId":"NCT05978622","phase":"","title":"Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-10-30","conditions":"Diabetic Macular Edema","enrollment":236},{"nctId":"NCT07099222","phase":"PHASE1, PHASE2","title":"Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arizona","startDate":"2024-10-10","conditions":"Postoperative Pain, Nausea and Vomiting, Postoperative, Dizziness","enrollment":100},{"nctId":"NCT06406829","phase":"NA","title":"Perioperative Multimodal Analgesia Protocol for Supratentorial Craniotomy","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2026-02-09","conditions":"Postoperative Pain, Analgesia, Supratentorial Brain Tumor","enrollment":2000},{"nctId":"NCT03710772","phase":"PHASE2","title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-01","conditions":"Mantle Cell Lymphoma","enrollment":51},{"nctId":"NCT02858804","phase":"PHASE4","title":"EDOCH Alternating With DHAP for New Diagnosed Younger MCL","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-01","conditions":"Mantle Cell Lymphoma","enrollment":55},{"nctId":"NCT04162210","phase":"PHASE3","title":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2021-03-24","conditions":"Multiple Myeloma","enrollment":325},{"nctId":"NCT06132685","phase":"PHASE2","title":"Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-09","conditions":"Low Grade Glioma, Malignant Brain Glioma, Malignant Brain Neoplasm","enrollment":200},{"nctId":"NCT07101445","phase":"PHASE4","title":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-24","conditions":"Multiple Myeloma","enrollment":94},{"nctId":"NCT05651932","phase":"PHASE1","title":"A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"K36 Therapeutics, Inc.","startDate":"2023-02-22","conditions":"Multiple Myeloma, Myeloma, Myeloma Multiple","enrollment":125},{"nctId":"NCT03031730","phase":"PHASE1","title":"Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-14","conditions":"Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":35},{"nctId":"NCT07398066","phase":"NA","title":"DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery (DEX-NEURO Trial)","status":"NOT_YET_RECRUITING","sponsor":"University of Malaya","startDate":"2026-07-22","conditions":"Neurosurgery, Brain Cancer, Meningioma","enrollment":60},{"nctId":"NCT07393074","phase":"NA","title":"PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC)","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-02-01","conditions":"Hepato Cellular Carcinoma, Cirrhosis, Autonomic Nervous System","enrollment":100},{"nctId":"NCT07231926","phase":"NA","title":"Intrathecal Morphine for Recovery and Outcomes After VATS","status":"RECRUITING","sponsor":"Ataturk University","startDate":"2025-12-01","conditions":"Postoperative Pain Management in Video-Assisted Thoracoscopic Surgery","enrollment":52},{"nctId":"NCT05497804","phase":"PHASE2","title":"Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-09-22","conditions":"ISS Stage III Plasma Cell Myeloma, Multiple Myeloma","enrollment":17},{"nctId":"NCT07385131","phase":"","title":"Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-10-08","conditions":"Inflammatory Bowel Disease (IBD), CD - Crohn's Disease, UC - Ulcerative Colitis","enrollment":300},{"nctId":"NCT07180953","phase":"PHASE4","title":"Impact of Dexamethasone Route on Pain and Inflammation in iPACK With ACB for Knee Arthroplasty","status":"RECRUITING","sponsor":"Poznan University of Medical Sciences","startDate":"2025-09-01","conditions":"Osteoarthritis, Knee, Knee Pain Chronic, Arthropathy of Knee","enrollment":90},{"nctId":"NCT05981209","phase":"PHASE1","title":"Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies","status":"RECRUITING","sponsor":"Abdullah Khan","startDate":"2023-12-21","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":27},{"nctId":"NCT05929001","phase":"","title":"Lymphedema Specific PROs for Risk Assessment, Prevention and Early Detection","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2021-01-13","conditions":"Lymphedema","enrollment":101},{"nctId":"NCT04681105","phase":"PHASE1","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-11-18","conditions":"Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":13},{"nctId":"NCT06755996","phase":"NA","title":"Dexmedetomidine Nasal Spray and Pediatric Bronchoscopy","status":"COMPLETED","sponsor":"Tongji Hospital","startDate":"2025-01-07","conditions":"Fiberoptic Bronchoscopy","enrollment":150},{"nctId":"NCT07350668","phase":"PHASE3","title":"Opioid-Free vs Opioid-Based Anesthesia for Nasal Surgeries","status":"COMPLETED","sponsor":"Benha University","startDate":"2025-01-01","conditions":"Postoperative Pain","enrollment":60},{"nctId":"NCT06616584","phase":"PHASE2, PHASE3","title":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2025-05-22","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":378},{"nctId":"NCT07362914","phase":"PHASE3","title":"Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-07","conditions":"Breast Cancer","enrollment":182},{"nctId":"NCT05070247","phase":"PHASE1, PHASE2","title":"A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Takeda","startDate":"2022-04-14","conditions":"Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma","enrollment":61},{"nctId":"NCT02718833","phase":"PHASE2","title":"A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2016-06-21","conditions":"Multiple Myeloma","enrollment":52},{"nctId":"NCT07194694","phase":"PHASE3","title":"Dexmedetomidine vs Ketamine as Adjuvants to Bupivacaine in Transversus Abdominus Plane Block in Inguinal Hernioplasty","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2025-10-22","conditions":"Postoperative Pain Relief","enrollment":60},{"nctId":"NCT07044557","phase":"NA","title":"MeDex: No Perioperative Dexamethasone in Brain Metastases","status":"RECRUITING","sponsor":"University of Louisville","startDate":"2025-12-03","conditions":"Brain Metastases","enrollment":35},{"nctId":"NCT05922501","phase":"PHASE2","title":"Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-05-31","conditions":"Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma","enrollment":50},{"nctId":"NCT06967857","phase":"PHASE2","title":"Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression","status":"RECRUITING","sponsor":"Prof. Dr. Frank Behrens","startDate":"2025-05-15","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD), Depression - Major Depressive Disorder","enrollment":105},{"nctId":"NCT07332130","phase":"PHASE1","title":"Spinal Analgesia in Labour Pain","status":"NOT_YET_RECRUITING","sponsor":"Minia University Hospital","startDate":"2025-12-24","conditions":"Labour Analgesia","enrollment":100},{"nctId":"NCT03030261","phase":"PHASE2","title":"Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-11-22","conditions":"Multiple Myeloma in Relapse","enrollment":25},{"nctId":"NCT03808610","phase":"PHASE1, PHASE2","title":"Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-03","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT03366155","phase":"PHASE2","title":"Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-24","conditions":"Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma","enrollment":24},{"nctId":"NCT00501826","phase":"PHASE2","title":"Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07-11","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":160},{"nctId":"NCT06639659","phase":"NA","title":"Sphenopalatine Block vs Dexmedetomidine Infusion in Trans Nasal Endoscopic Pituitary Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zagazig University","startDate":"2024-10-01","conditions":"Sphenopalatine Ganglion Nerve Block, Transnasal Endoscopic Pitutary Surgery","enrollment":69},{"nctId":"NCT07072585","phase":"PHASE2, PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma","enrollment":1708},{"nctId":"NCT03583255","phase":"PHASE2","title":"Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-06-29","conditions":"Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Malignant Solid Neoplasm","enrollment":99},{"nctId":"NCT06042725","phase":"PHASE1","title":"MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-04","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT01665794","phase":"PHASE1, PHASE2","title":"Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2012-08-13","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT03543371","phase":"","title":"Neuropsychological Outcome After Cardiac Arrest","status":"COMPLETED","sponsor":"Region Skane","startDate":"2018-07-13","conditions":"Heart Arrest, Out-Of-Hospital, Hypoxia-Ischemia, Brain, Cognition Disorders","enrollment":200},{"nctId":"NCT03180736","phase":"PHASE3","title":"Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex","status":"COMPLETED","sponsor":"Stichting European Myeloma Network","startDate":"2017-06-14","conditions":"Multiple Myeloma","enrollment":304},{"nctId":"NCT06387121","phase":"PHASE2","title":"Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-02","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":53},{"nctId":"NCT06936449","phase":"","title":"Long-term Follow-up of a Cochlear Implant With Dexamethasone Eluting Electrode Array","status":"RECRUITING","sponsor":"Cochlear","startDate":"2025-05-05","conditions":"Sensorineural Hearing Loss, Bilateral Hearing Loss","enrollment":19},{"nctId":"NCT02795871","phase":"NA","title":"Prenatal Dex Study","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-10-04","conditions":"Congenital Adrenal Hyperplasia","enrollment":354},{"nctId":"NCT01435798","phase":"PHASE2","title":"Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan Dose Response Clinical Trial","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2003-04","conditions":"Central Neuropathic Pain, Allodynia, Spinal Cord Injury","enrollment":26},{"nctId":"NCT02218203","phase":"PHASE2","title":"Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2003-04","conditions":"Central Neuropathic Pain, Allodynia, Spinal Cord Injury","enrollment":26},{"nctId":"NCT01424982","phase":"PHASE2","title":"Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-10-05","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission","enrollment":88},{"nctId":"NCT07241351","phase":"PHASE2, PHASE3","title":"Dexmedetomidine as an Adjunct to Fentanyl for Term Neonates on Mechanical Ventilation","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-03-01","conditions":"Analgesia, Sedation and Analgesia, Neonatal","enrollment":40},{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":"Recurrent B Acute Lymphoblastic Leukemia","enrollment":669},{"nctId":"NCT02112916","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-04","conditions":"Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma","enrollment":847},{"nctId":"NCT04289142","phase":"PHASE4","title":"Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2019-12-01","conditions":"Delirium, Cognitive Dysfunction, Cognition Disorder","enrollment":2400},{"nctId":"NCT07073846","phase":"PHASE4","title":"Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery.","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-10-06","conditions":"Morbid Obesity Requiring Bariatric Surgery, Postoperative Pain, Postoperative Pain Management","enrollment":104},{"nctId":"NCT02003222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-19","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":488},{"nctId":"NCT00098475","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-11-03","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":452},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia","enrollment":5949},{"nctId":"NCT06352593","phase":"NA","title":"Intraoperative Dexmedetomidine Infusion in Endovascular Intervention for Aneurysmal Subarachnoid Hemorrhage","status":"COMPLETED","sponsor":"Tanta University","startDate":"2024-04-06","conditions":"Dexmedetomidine, Infusion, Endovascular","enrollment":90},{"nctId":"NCT02970747","phase":"","title":"Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2016-10-25","conditions":"Multiple Myeloma in Relapse","enrollment":359},{"nctId":"NCT03466242","phase":"EARLY_PHASE1","title":"IN Dexmedetomidine for Procedural Sedation in Pediatric Closed Reductions for Distal Forearm Fractures","status":"WITHDRAWN","sponsor":"Phoenix Children's Hospital","startDate":"2017-01-01","conditions":"Conscious Sedation, Distal Radius Fracture","enrollment":""},{"nctId":"NCT04891289","phase":"PHASE2","title":"Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-07","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":164}],"_emaApprovals":[],"_faersSignals":[{"count":48,"reaction":"TOXICITY TO VARIOUS AGENTS"},{"count":33,"reaction":"UNEVALUABLE EVENT"},{"count":31,"reaction":"FATIGUE"},{"count":29,"reaction":"OFF LABEL USE"},{"count":28,"reaction":"DRUG INEFFECTIVE"},{"count":24,"reaction":"NAUSEA"},{"count":24,"reaction":"PERITONITIS"},{"count":23,"reaction":"RASH"},{"count":21,"reaction":"DEATH"},{"count":21,"reaction":"THROMBOCYTOPENIA"}],"_approvalHistory":[],"publicationCount":14481,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ropivacaine/dex","dexmedetomidine group"],"phase":"marketed","status":"active","brandName":"dex","genericName":"dex","companyName":"The Cleveland Clinic","companyId":"the-cleveland-clinic","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that induces sedation and reduces sympathetic nervous system activity. Used for Sedation in intensive care unit (ICU) patients, Sedation in procedural sedation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}